← All trials
NCT05863195
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Dec 19, 2023
- Primary completion
- Jun 30, 2029
- Completion date
- Jun 30, 2034
- First posted
- May 17, 2023
- Last posted
- May 17, 2023
- Enrollment
- 408
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- ECOG-ACRIN Cancer Research GroupLead sponsor
- National Cancer Institute (NCI)Collaborator
- ECOG-ACRIN Cancer Research GroupOverall official - principal investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.